

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A medicament having an inhibitory action against activation of a transcription factor KLF5, ~~which comprises~~ the medicament comprising an acyclic polyprenyl compound as an active ingredient.
2. (Currently Amended) A medicament having an inhibitory action against vascular remodeling, ~~which comprises~~ the medicament comprising an acyclic polyprenyl compound as an active ingredient.
3. (Currently Amended) A medicament having an inhibitory action against arteriosclerosis, ~~which comprises~~ the medicament comprising an acyclic polyprenyl compound as an active ingredient.
4. (Currently Amended) The medicament according to ~~any one of claims claim 1 to 3~~, wherein the acyclic polyprenyl compound is a polyprenylcarboxylic acid.
5. (Currently Amended) The medicament according to ~~any one of claims claim 1 to 3~~, wherein the acyclic polyprenyl compound is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
6. (Currently Amended) The medicament according to ~~any one of claims claim 1 to 3~~, wherein the acyclic polyprenyl compound is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
7. (Currently Amended) The medicament according to ~~any one of claims claim 1 to 6~~, which is in the form of a pharmaceutical composition containing a pharmaceutically

acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.

8. (Currently Amended) The medicament according to ~~any one of claims~~ claim 1 to 7, which is in the form of a pharmaceutical composition for oral administration.
9. (New) The medicament according to claim 2, wherein the acyclic polyprenyl compound is a polyprenylcarboxylic acid.
10. (New) The medicament according to claim 3, wherein the acyclic polyprenyl compound is a polyprenylcarboxylic acid.
11. (New) The medicament according to claim 2, wherein the acyclic polyprenyl compound is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
12. (New) The medicament according to claim 3, wherein the acyclic polyprenyl compound is 3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
13. (New) The medicament according to claim 2, wherein the acyclic polyprenyl compound is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
14. (New) The medicament according to claim 3, wherein the acyclic polyprenyl compound is (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentanoic acid.
15. (New) The medicament according to claim 2, which is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.
16. (New) The medicament according to claim 3, which is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.

17. (New) The medicament according to claim 4, which is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.
18. (New) The medicament according to claim 5, which is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.
19. (New) The medicament according to claim 6, which is in the form of a pharmaceutical composition containing a pharmaceutically acceptable additive for formulations together with an acyclic polyprenyl compound as an active ingredient.
20. (New) The medicament according to claim 2, which is in the form of a pharmaceutical composition for oral administration.